ZYXI vs DBVT

Zynex, Inc.

(ZYXI) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, DBV Technologies S.

A. (DBVT) delivered a total return of -69. 1%, compared to -98. 9% for Zynex, Inc. (ZYXI). Over 10 years, the gap is even starker: ZYXI returned -29. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Zynex, Inc. 's 4. 55β — meaning ZYXI is approximately 262% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 2% for Zynex, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Zynex, Inc.

grew EPS -66. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zynex, Inc.

(ZYXI) is the more profitable company, earning 1. 6% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 1. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYXI leads at 3. 1% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ZYXI leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ZYXI (0.

5% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DBV Technologies S.

A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Zynex, Inc. (ZYXI) carries a higher beta of 4. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, ZYXI: -29. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZYXI is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock. ZYXI pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.